PRTK - Paratek Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
9.65
+0.40 (+4.32%)
At close: 4:00PM EDT

9.60 -0.05 (-0.52%)
Pre-market: 9:28AM EDT

Stock chart is not supported by your current browser
Previous close9.25
Open9.20
Bid9.45 x 3200
Ask9.75 x 4000
Day's range9.15 - 9.70
52-week range9.00 - 26.10
Volume562,490
Avg. volume554,991
Market cap306.191M
Beta0.65
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend date2014-10-31
1y target estN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire20 days ago

    Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

    Paratek Pharmaceuticals, Inc. (PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, today announced that on August 31, 2018, the Company granted stock options and restricted stock units to three new employees of the Company.

  • GlobeNewswire26 days ago

    Paratek Pharmaceuticals to Present at Baird's 2018 Global Healthcare Conference

    Paratek Pharmaceuticals, Inc. (PRTK) today announced that it will present at Baird's 2018 Global Healthcare Conference on Wednesday, September 5 at 10:15 a.m. EDT at the InterContinental New York Barclay in New York. To access the live webcast of Paratek's presentation, please visit http://wsw.com/webcast/baird52/prtk/. Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry.

  • GlobeNewswire2 months ago

    FDA Advisory Committee Recommends Approval of Paratek’s Omadacycline

    Paratek Pharmaceuticals, Inc. (PRTK) today announced that the Antimicrobials Drug Advisory Committee of the U.S. Food and Drug Administration voted in favor of the approval of intravenous (IV) and oral omadacycline for the treatment of acute bacterial skin and skin structure infections (ABSSSI) (17-1) and community-acquired bacterial pneumonia (CABP) (14-4).  Omadacycline is a modernized tetracycline being developed as a once-daily IV and oral, broad spectrum antibiotic for the treatment of serious community-acquired infections. “Omadacycline has the potential to help address the urgent and growing need for new antibiotics to treat serious community-acquired infections.

  • GlobeNewswire2 months ago

    Paratek Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Review Omadacycline New Drug Applications for the Treatment of Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infections

    Paratek Pharmaceuticals, Inc. (PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, today announced that NASDAQ has halted trading of the company’s common stock. The Advisory Committee meeting is scheduled from 8:30 a.m. to 1 p.m. ET.  The briefing materials can be found on the FDA website.

  • GlobeNewswire2 months ago

    Paratek Pharmaceuticals Reports Second Quarter 2018 Financial Results

    --Antimicrobial Drugs Advisory Committee of FDA scheduled for August 8, 2018 to review the Company's NDAs for omadacycline--. --Omadacycline PDUFA action date scheduled for October 2018--. --Company on ...

  • GlobeNewswire2 months ago

    Paratek Pharmaceuticals to Report Second Quarter 2018 Financial Results on August 2, 2018

    Paratek Pharmaceuticals, Inc. (PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, announced today that it will host a conference call and live audio webcast on Thursday, August 2, 2018 at 4:30 p.m. EDT to report second quarter 2018 financial results and provide a corporate update. Domestic investors wishing to participate in the call should dial: 866-575-6539 and international investors should dial: 323-994-2082. Domestic investors can access the replay by dialing 844-512-2921 and international investors can access the replay by dialing 412-317-6671.

  • PR Newswire5 months ago

    Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

    71 Abstracts to be Presented by Coalition Members During the Annual Meeting WASHINGTON , April 20, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG) today announced that thirteen of its member ...